Angle PLC - Guildford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a clinical-stage biotech company. It will launch with a fully-funded pilot study. Further details are confidential between the two companies.

Chief Executive Andrew Newland says: ‘Whilst the study is modest in size during the pilot phase, there is the potential for larger follow-on contracts in the event of a successful pilot study. Recursion has partnerships with multiple leading large pharma companies and this agreement, Angle’s fourth for 2024, further builds on the expansion of our large pharma services business.’

Current stock price: 11.12 pence per share, up 3.4% in London on Thursday afternoon

12-month change: down 26%

Copyright 2024 Alliance News Ltd. All Rights Reserved.